Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of ...
The UK’s drug’s watchdog has warned people over the use of counterfeit medications which could contain insulin - with many ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
The NHS rollout of appetite suppressing injections has been thrown into doubt after what is believed to be the first confirmed death linked to the controversial drugs ...
The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...
As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...
Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback